USP7 interacts with and destabilizes oncoprotein SET.

Oncoprotein SE translocation (SET) is frequently overexpressed in different types of tumors and correlated with poor prognosis of cancer patients. Targeting SET has been considered a promising strategy for cancer intervention. However, the mechanisms by which SET is regulated under cellular conditions are largely unknown. Here, by performing a tandem affinity purification-mass spectrometry (TAP-MS), we identify that the ubiquitin-specific protease 7 (USP7) forms a stable protein complex with SET in cancer cells. Further analyses reveal that the acidic domain of SET directly binds USP7 while both catalytic domain and ubiquitin-like (UBL) domains of USP7 are required for SET binding. Knockdown of USP7 has no effect on the mRNA level of SET. However, we surprisingly find that USP7 depletion leads to a dramatic elevation of SET protein levels, suggesting that USP7 plays a key role in destabilizing oncoprotein SET, possibly through an indirect mechanism. To our knowledge, our data report the first deubiquitinase (DUB) that physically associates with oncoprotein SET and imply an unexpected regulatory effect of USP7 on SET stability.

Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2.

Posttranslational modifications represent a key step in modulating programmed death-1 (PD-1) functions, but the underlying mechanisms remain incompletely defined. Here, we report crosstalk between deglycosylation and ubiquitination in regulating PD-1 stability. We show that the removal of N-linked glycosylation is a prerequisite for efficient PD-1 ubiquitination and degradation. Murine double minute 2 (MDM2) is identified as an E3 ligase of deglycosylated PD-1. In addition, the presence of MDM2 facilitates glycosylated PD-1 interaction with glycosidase NGLY1 and promotes subsequent NGLY1-catalyzed PD-1 deglycosylation. Functionally, we demonstrate that the absence of T cell-specific MDM2 accelerates tumor growth by primarily upregulating PD-1. By stimulating the p53-MDM2 axis, interferon-α (IFN-α) reduces PD-1 levels in T cells, which, in turn, exhibit a synergistic effect on tumor suppression by sensitizing anti-PD-1 immunotherapy. Our study reveals that MDM2 directs PD-1 degradation via a deglycosylation-ubiquitination coupled mechanism and sheds light on a promising strategy to boost cancer immunotherapy by targeting the T cell-specific MDM2-PD-1 regulatory axis.

The repression of oncoprotein SET by the tumor suppressor p53 reveals a p53-SET-PP2A feedback loop for cancer therapy.

The oncoprotein SET is frequently overexpressed in many types of tumors and contributes to malignant initiation and progression through multiple mechanisms, including the hijacking of the tumor suppressors p53 and PP2A. Targeting aberrant SET represents a promising strategy for cancer intervention. However, the mechanism by which endogenous SET is regulated in cancer cells remains largely unknown. Here, we identified the tumor suppressor p53 as a key regulator that transcriptionally repressed the expression of SET in both normal and cancer cells. In addition, p53 stimulated PP2A phosphatase activity via p53-mediated transcriptional repression of SET, whereby SET-mediated inhibition of PP2A was alleviated. Moreover, targeting the interaction between SET and PP2A catalytic subunit (PP2Ac) with FTY720 enhanced stress-induced p53 activation via PP2A-mediated dephosphorylation of p53 on threonine 55 (Thr55). Therefore, our findings uncovered a previously unknown p53-SET-PP2A regulatory feedback loop. To functionally potentiate this feedback loop, we designed a combined therapeutic strategy by simultaneously administrating a p53 activator and SET antagonist in cancer cells and observed a dramatic synergistic effect on tumor suppression. Our study reveals mechanistic insight into the regulation of the oncoprotein SET and raises a potential strategy for cancer therapy by stimulating the p53-SET-PP2A feedback loop.

Determination of Kaurenoic Acid in Acanthopanax trifoliatus by Ultra-High Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry (UHPLC-MS/MS).

Acanthopanax trifoliatus (L.) Merr. (A. trifoliatus) belongs to the family Araliaceae, which is called "Le Cai", and is an indigenous plant to Guangdong Province that has been prevalently planted for years. A. trifoliatus is used in folk medicine and has ginseng-like activity. Kaurenoic acid ((-)-kaur-16-en-19-oic acid, KA) is a kaurane-type diterpenoid that is regarded as a major compound in A. trifoliatus. Early studies have reported the determination of KA by HPLC capillary electrophoresis. However, KA could not be completely separated from other components in the plant extract by HPLC because of their similar molecular structures and physical and chemical properties. UHPLC-MS/MS could be a useful tool to identify and quantify KA. In the present work, a UHPLC-ESI-MS/MS method for determining KA in A. trifoliatus was developed and validated. KA was extracted from lyophilized A. trifoliatus leaves by ultrasound-assisted extraction and further purified by solid phase extraction (SPE). KA was quantified and separated on an Accucore C18 LC column. Mass spectrometry with multi-reaction monitoring (MRM) and quantitative fragment ion/product ion (m/z: 301.3/301.3) in ESI negative mode was used for quantification. The intra-assay and inter-assay relative standard deviation (R.S.D.) were 2.8% and 3.2%, respectively. The inter-person R.S.D. on the same day was 3.6%. The inter-instrument R.S.D. with the same model on the same day was 2.9%. The recoveries evaluated upon spiking three different concentrations of KA were above 97%. A minor matrix effect of 94% was observed. This method has been applied successfully for the determination of KA in A. trifoliatus leaves.

Activated carbon fibers impregnated with Pd and Pt catalysts for toluene removal.

Few studies have investigated the use of activated carbon fibers (ACFs) impregnated with noble metals for the catalytic oxidation of volatile organic compounds (VOCs). This study determined the removal efficiency of toluene as a function of time over ACF-supported metal catalysts. Two catalysts (Pt and Pd), five reaction temperatures (120, 150, 200, 250, and 300°C), and three oxygen contents (6%, 10%, and 21%) were investigated to determine the removal of toluene. To study the effects of the characteristics of the catalysts on toluene removal, the composition and morphology of the ACFs were analyzed using the BET, XPS, ICP, and FE-SEM. The results showed that the 0.42%Pd/ACFs showed greater activity for toluene removal than did 2.68%Pt/ACFs at a reaction temperature of 200°C and an oxygen content of 10%. The main removal mechanism of toluene over the 2.68%Pt/ACFs at reaction temperatures less than 200°C was adsorption. The long-term catalytic activity of the 2.68%Pt/ACFs for toluene removal at a reaction temperature of 250°C and an oxygen content of 10% could be obtained. Furthermore, toluene removal over the 2.68%Pt/ACFs at 200°C could be enhanced with increasing oxygen content.

Metal catalysts supported on activated carbon fibers for removal of polycyclic aromatic hydrocarbons from incineration flue gas.

The aim of this research was to use metal catalysts supported on activated carbon fibers (ACFs) to remove 16 species of polycyclic aromatic hydrocarbons (PAHs) from incineration flue gas. We tested three different metal loadings (0.11 wt%, 0.29 wt%, and 0.34 wt%) and metals (Pt, Pd, and Cu), and two different pretreatment solutions (HNO(3) and NaOH). The results demonstrated that the ACF-supported metal catalysts removed the PAHs through adsorption and catalysis. Among the three metals, Pt was most easily adsorbed on the ACFs and was the most active in oxidation of PAHs. The mesopore volumes and density of new functional groups increased significantly after the ACFs were pretreated with either solutions, and this increased the measured metal loading in HNO(3)-0.48% Pd/ACFs and NaOH-0.52% Pd/ACFs. These data confirm that improved PAH removal can be achieved with HNO(3)-0.48% Pd/ACFs and NaOH-0.52% Pd/ACFs.